Archive · 20 Sep 2026
ENTOD Secures Patent for Insulin Eye Drops in India
ENTOD Pharmaceuticals has received a patent for eye drops containing insulin.
Insulin is usually known as a medicine for people with diabetes.
Researchers are studying whether it could also help treat certain eye problems.
The eye drops are still being tested in the early, pre-clinical stage.
This means they have not yet been proven safe or useful for patients.
More laboratory work and clinical studies will be needed.
A doctor said the idea is scientifically interesting because it uses a familiar molecule in a new way.
ENTOD said the work shows that Indian companies are developing original medicines.
ENTOD Pharmaceuticals announced patent approval for its topical insulin eye drops.
The eye drops are currently in pre-clinical development and have not yet been established as safe or effective.
The company is investigating the treatment as a potential new approach for unmet needs in eye care.
Further pre-clinical and clinical studies are required to determine safety, efficacy and possible uses.
ENTOD described the patent as evidence of India’s growing pharmaceutical research and innovation capabilities.
- Who
- ENTOD Pharmaceuticals, led in the announcement by CEO Nikkhil K Masurkar, and researchers commenting on the work.
- What
- The company announced patent approval for topical insulin eye drops.
- When
- The announcement was reported on September 19; the year was not specified.
- Where
- The report was datelined New Delhi, while ENTOD Pharmaceuticals is based in Mumbai and comments came from Hyderabad.
- Why
- The eye drops are being investigated as a potential new treatment for unmet needs in ophthalmic care and as an example of indigenous pharmaceutical innovation.
Potential Innovation
Need for Further Evidence
Medical potential
Potential Innovation
ENTOD says the eye drops could open new avenues in ophthalmic treatment and address unmet needs in eye care.
Need for Further Evidence
The treatment’s safety, therapeutic value and clinical applications have not yet been established and require rigorous research.
Significance of the patent
Potential Innovation
ENTOD describes the patent as a sign of India’s growing ability to create original pharmaceutical innovations.
Need for Further Evidence
A patent protects the invention but does not by itself demonstrate that the eye drops are safe or effective for patients.
- Company
- ENTOD Pharmaceuticals
- Product
- Topical insulin eye drops
- Development stage
- Pre-clinical
- Patent status
- Patent approval announced
- Research area
- Ophthalmic care
- Evidence still needed
- Further pre-clinical and clinical research on safety, efficacy and clinical applications
- Scientific comment
- The approach explores insulin through a different route of delivery